Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients

Chimeric antigen receptor T cell (CAR-T) therapy has emerged as highly effective in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but only about 40% patients have achieved sustained responses. Here, we conducted a phase II clinical trial testing efficacy and toxicities of CAR-T th...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Changju, Zou, Rui, Wang, Peng, Zhu, Qian, Kang, Liqing, Ping, Nana, Xia, Fan, Liu, Hailing, Kong, Danqing, Yu, Lei, Wu, Depei, Jin, Zhengming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429371/
https://www.ncbi.nlm.nih.gov/pubmed/36059523
http://dx.doi.org/10.3389/fimmu.2022.969660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429371/
https://www.ncbi.nlm.nih.gov/pubmed/36059523
http://dx.doi.org/10.3389/fimmu.2022.969660

Ejemplares similares